GlassScriptPhysician profile
Purvi Parikh
NPI 1346229838
$1,113.96
in general payments reported to CMS, 2019-2025
20 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $111 · 2021: $136 · 2022: $147 · 2023: $182 · 2024: $183 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $573.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $200.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $164.80 | 2019-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $144.91 | 2020-2025 | Korlym |
| Medtronic, INC. | $107.27 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Recordati_rare_diseases_inc. | $85.53 | 2024-2025 | Isturisa, Signifor Lar |
| Sanofi-Aventis U.S. LLC | $73.27 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $71.01 | 2023-2024 | |
| Medtronic Minimed, INC. | $39.65 | 2020 | |
| Genentech USA, INC. | $39.55 | 2025 | Xolair |
| Xeris Pharmaceuticals, INC. | $32.79 | 2025 | Recorlev |
| Abbvie INC. | $27.66 | 2022-2024 | |
| Kyowa Kirin, INC. | $17.06 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $15.68 | 2022 | |
| Globus Medical, INC. | $15.06 | 2025 | Senza |
| Merck Sharp & Dohme LLC | $14.37 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $14.15 | 2022 | |
| Ascensia Diabetes Care US INC. | $13.90 | 2019 | |
| Averitas Pharma INC. | $13.27 | 2023 | Qutenza |
| Lilly USA, LLC | $12.00 | 2020 | |
| Tandem Diabetes Care, INC. | $11.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Purvi Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.